A Phase 1/2, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Latest Information Update: 08 May 2025
At a glance
Most Recent Events
- 29 Apr 2025 Planned End Date changed from 20 Nov 2025 to 20 Nov 2026.
- 29 Apr 2025 Planned primary completion date changed from 14 Apr 2025 to 14 Apr 2026.
- 13 Sep 2024 Planned End Date changed from 14 Apr 2025 to 20 Nov 2025.